Roswell Park Cancer Institute Plans Spring 1998 Move to its New Campus

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 12
Volume 6
Issue 12

BUFFALO, NY-In 1998, the year of its 100th anniversary celebration, Roswell Park Cancer Institute will move into its new $241 million campus, including a new hospital building (see photograph) and major renovations.

BUFFALO, NY—In 1998, the year of its 100th anniversary celebration, Roswell Park Cancer Institute will move into its new $241 million campus, including a new hospital building (see photograph) and major renovations.

Founded in 1898, Roswell Park was the first cancer research, treatment, and education center in the United States, according to a spokesperson for the center. The new construction has been overseen by David C. Hohn, MD, president and CEO of the Institute since January 1997.

Another important landmark for the NCI-designated comprehensive cancer center is the implementation of legislation passed into law by the New York State Legislature last summer that will begin Roswell Park’s transition from a public institution to a public benefit corporation. The new designation is aimed at allowing Roswell Park greater flexibility to respond to changes in the health care marketplace and thus compete more effectively with private cancer centers.

Specifically, the legislation creates the Roswell Park Cancer Institute Corporation with a 15-member board of directors, appointed by the governor and various New York State Senate and Assembly leaders. The new corporation may negotiate contracts with managed care networks and participate in other joint and cooperative arrangements for the provision of comprehensive and specialty health care services.

The legislation also allows the corporation to establish new subsidiary corporations and other entities to meet the demands of the changing health care market and to develop and market products or services that result from its clinical and research activities.

A spokesperson for the Institute said that with its new status, Roswell Park will begin producing many of the cancer therapies discovered by its researchers rather than selling the rights to these products to pharmaceutical companies.

The transition from a state facility operated by the New York State Department of Health to a public benefit corporation is expected to be completed in about a year.

Recent Videos
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
The use of enhanced imaging and adaptive radiotherapy has lessened the burden on patients with cancer receiving radiotherapy as treatment.
7 experts are featured in this series.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Related Content